Improved survival with simendan after experimental myocardial infarction in rats.
This study compared the effects of simendan, a calcium sensitizer, with those of milrinone and enalapril on survival of rats with healed myocardial infarction. Seven days after ligation-induced myocardial infarction, the rats were randomized to control, milrinone, enalapril, or simendan groups. All compounds were administered via the drinking water for 312 days, at which time there was 80% mortality in the control group--the study's primary endpoint. The infarct sizes were similar across all groups. At endpoint, the mortality rates were: 63% (milrinone), 56% (enalapril) and 53% (simendan); the risk reductions were 25% (P = 0.04 vs. control) and 28% (P = 0.02 vs. control) with enalapril and simendan, respectively. Milrinone had no statistically significant effect on the survival rate. These findings suggest that, like enalapril, simendan improved survival in rats with healed myocardial infarction.
Levijoki
J
J
Cardiovascular Research, Orion Pharma, Espoo, Finland. jouko.levijoki@orionpharma.com
Pollesello
P
P
Kaheinen
P
P
Haikala
H
H
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004656:Enalapril / Q000627:therapeutic use*; D006835:Hydrazones / Q000627:therapeutic use*; D008297:Male; D020105:Milrinone / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D011724:Pyridazines / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D000077464:Simendan
D000959:Antihypertensive Agents; D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan; D004656:Enalapril; D020105:Milrinone